Key result
Perioperative intravenous amiodarone increased the incidence of postoperative atrial fibrillation compared to placebo (59.3% vs 40.0%; P=0.035) in patients undergoing cardiac valvular surgery.
Why the study?
Does intravenous amiodarone prevent postoperative atrial fibrillation in patients undergoing cardiac valvular surgery?
Population
120 patients undergoing cardiac valvular surgery, mean age 65 +/- 11 yr.
Comparison
Intravenous amiodarone vs Placebo
Design
RCT, randomly assigned, double-blinded, double-dummy
Follow-up
postoperative period
Authors
Loading...
Perioperative IV amiodarone should be avoided for POAF prevention in valvular surgery; challenges assumptions of benefit from prior prophylaxis trials.
RCT (n=120)
double-blinded, double-dummy
randomized
No
Does intravenous amiodarone prevent postoperative atrial fibrillation in patients undergoing cardiac valvular surgery?
Absolute Event Rate: 59.3% vs 40%
p-value: p=0.035
Perioperative intravenous amiodarone for 48 hours does not reduce, and may paradoxically increase, the risk of postoperative atrial fibrillation in patients undergoing cardiac valvular surgery.
Beaulieu et al. (2009) conducted an RCT in postoperative atrial fibrillation (n=120). Intravenous amiodarone vs. placebo was evaluated on development of atrial fibrillation occurring at any time within the postoperative period (p=0.035). Perioperative intravenous amiodarone increased the incidence of postoperative atrial fibrillation compared to placebo (59.3% vs 40.0%; P=0.035) in patients undergoing cardiac valvular surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: